

## HAMPSHIRE COUNTY COUNCIL

### Covering Report

<b>Committee:</b>	Hampshire Health and Wellbeing Board		
<b>Date:</b>	6 October 2022		
<b>Title:</b>	Hampshire County Council Pharmaceutical Needs Assessment 2022-2025		
<b>Report From:</b>	Simon Bryant, Director of Public Health		
<b>Contact name:</b>	Jenny Bowers		
<b>Tel:</b>	0370 779 2612	<b>Email:</b>	<a href="mailto:Jenny.Bowers@hants.gov.uk">Jenny.Bowers@hants.gov.uk</a>

#### Purpose of this Report

1. The purpose of this report is to sign off the Pharmaceutical Needs Assessment 2022-2025 following public consultation.

#### Recommendation(s)

2. That the Hampshire Health and Wellbeing Board approve the Pharmaceutical Needs Assessment 2022-2025 prior to publication.

#### Background

3. Since April 2013 every Health and Wellbeing Board in England has a legal responsibility to publish and keep up to date a statement of the needs for pharmaceutical services of the population in its area, referred to as a pharmaceutical needs assessment (PNA). The PNA looks at existing provision of community pharmacy services across Hampshire, whether this meets the current and future needs of the population and identifies any gaps in current or future provision.
4. The PNA has been undertaken in line with the requirements of the NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations and the latest guidance published in the information pack for local authority health and wellbeing boards in October 2014. The current Hampshire PNA has been in development since September 2021.

5. The purpose of the pharmaceutical needs assessment is primarily to be used by NHS England and the ICB to make market entry decisions. It will be used when applications are received to enter or amend the pharmaceutical list within the Hampshire HWB area. It may also be used by local authorities and clinical commissioning groups when commissioning services from pharmacies and dispensing appliance contractors, ensuring that services are targeted to areas of need.
6. The consultation ran for a period of 60 days from 4 April closing at 11.59pm on 3 June 2022.
7. The report and appendix are part of this paper including changes that have taken place since the publication of the draft PNA.

### Headline findings of the consultation

8. The consultation findings can be found in appendix 3
9. A total of 33 responses were received via the online form. Over half (n=19) were from members of the public.

<b>In what capacity are you responding to this questionnaire?</b>	<b>Count</b>
In another capacity not listed above	3
Personal view as a member of the public	19
Personal view as a pharmaceutical professional working in a community pharmacy	4
Representing the views of an organisation such as a Health and Wellbeing Board, Local Pharmaceutical Committee, Local Medical Committee, CCG etc	5
Unknown	2
<b>Total</b>	<b>33</b>

10. Overall the responses were positive with the majority of responses stating;
  - The purpose of the PNA had been explained (87% agreed/strongly agreed)
  - Draft PNA reflected the current provision in the area (77% agreed/strongly agreed)
  - Draft PNA identified gaps in service provision if appropriate (64% agreed/strongly agreed)

- Draft PNA reflected the needs of the area's population (56% agreed/strongly agreed)
- The draft PNA provides information to inform market entry decisions (83% agreed/strongly agreed)
- The draft PNA provides information to inform how pharmaceutical services may be commissioned in the future (100% agreed/strongly agreed)
- The draft PNA provides enough information to inform future pharmaceutical services provision and plans for pharmacies and dispensing appliance contractors. (75% agreed/strongly agreed)
- There are gaps in pharmaceutical services that could be provided in the community pharmacy setting in the future that have not been highlighted (50% disagree/strongly disagree)

### **Further considerations**

11. The complexity of pharmacy contracts does lend itself to quite a technical document, the scope of which is defined by national guidance which can be challenging to read.
12. The main purpose of the pharmaceutical needs assessment is to inform the submission of applications for inclusion in a pharmaceutical list, and the subsequent determination of such applications. This legislation does not require specific local data such as staffing and prescribing problems to be considered.
13. A number of changes have occurred since the consultation of the draft PNA a supplementary statement will be published as an addendum the final report.

### **Conclusion**

14. Following public consultation, the conclusion of the assessment is that the number, distribution, and choice of pharmaceutical services meets the current needs of Hampshire's population and future needs within the lifetime of this PNA. There are no identified needs for additional pharmaceutical services or improvements to current arrangements across the county.

**REQUIRED CORPORATE AND LEGAL INFORMATION:**

**Links to the Strategic Plan**

<b>Hampshire maintains strong and sustainable economic growth and prosperity:</b>	No
<b>People in Hampshire live safe, healthy and independent lives:</b>	Yes
<b>People in Hampshire enjoy a rich and diverse environment:</b>	No
<b>People in Hampshire enjoy being part of strong, inclusive communities:</b>	Yes

**Other Significant Links**

<b>Links to previous Member decisions:</b>	
<u>Title</u>	<u>Date</u>
Hampshire Pharmaceutical Needs Assessment	16 June 2022

**Section 100 D - Local Government Act 1972 - background documents**

The following documents discuss facts or matters on which this report, or an important part of it, is based and have been relied upon to a material extent in the preparation of this report. (NB: the list excludes published works and any documents which disclose exempt or confidential information as defined in the Act.)

<u>Document</u>	<u>Location</u>
None	

## **EQUALITIES IMPACT ASSESSMENT:**

### **1. Equality Duty**

The County Council has a duty under Section 149 of the Equality Act 2010 ('the Act') to have due regard in the exercise of its functions to the need to:

- Eliminate discrimination, harassment and victimisation and any other conduct prohibited by or under the Act with regard to the protected characteristics as set out in section 4 of the Act (age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex and sexual orientation);
- Advance equality of opportunity between persons who share a relevant protected characteristic within section 149(7) of the Act (age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex and sexual orientation) and those who do not share it;
- Foster good relations between persons who share a relevant protected characteristic within section 149(7) of the Act (see above) and persons who do not share it.

Due regard in this context involves having due regard in particular to:

- The need to remove or minimise disadvantages suffered by persons sharing a relevant protected characteristic that are connected to that characteristic;
- Take steps to meet the needs of persons sharing a relevant protected characteristic that are different from the needs of persons who do not share it;
- Encourage persons sharing a relevant protected characteristic to participate in public life or in any other activity in which participation by such persons is disproportionately low.

### **2. Equalities Impact Assessment:**

Please see Items 6-9.